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ABSTRACT 
 
Objectives: To assess the cost-effectiveness of bivalirudin versus heparin plus glycoprotein IIb/IIIa inhibitor (GPI) 
in thienopyridine-treated non-ST segment elevation acute coronary syndrome (NSTE-ACS) patients undergoing 
early or urgent invasive management, from a UK National Health Service perspective. 
 
Methods: A decision-analytic model with life-long time horizon was populated with event risks and resource use 
parameters derived from the ACUITY trial raw data. In a parallel analysis, key comparator strategy inputs came 
from GRACE registry patients enrolled in the UK. Upstream and catheter laboratory-initiated GPI was assumed to 
be tirofiban and abciximab, respectively. Life expectancy of first-year survivors, unit costs and health-state utilities 
came from UK sources. Costs and effects were discounted at 3.5%. Incremental cost-effectiveness ratios (ICERs) 
were expressed as cost per quality-adjusted life-year (QALY) gained. 
 
Results: Higher acquisition costs for bivalirudin were partially offset by lower hospitalisation and bleeding costs. In 
the ACUITY-based analysis, per-patient life-time costs in the bivalirudin and heparin plus GPI strategies were 
£10,903 and £10,653, respectively. Patients survived 10.87 and 10.82 years on average, corresponding to 5.96 and 
5.93 QALYs and resulting in an ICER of £9,906 per QALY gained. The GRACE-based ICER was £12,276 per 
QALY gained. In probabilistic sensitivity analysis, 72.1% (ACUITY-based) and 67.0% (GRACE-based) of 
simulation results were more cost-effective than £20,000 per QALY gained. Additional scenario analyses implied 
that greater cost-effectiveness may be achieved in actual clinical practice. 
 
Conclusions: Treating NSTE-ACS patients undergoing invasive management with bivalirudin is likely to represent a 
cost-effective option for the UK, when compared to current practice of using heparin and a GPI. 
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INTRODUCTION 
 
In patients with non-ST segment elevation acute coronary syndromes (NSTE-ACS), anti-platelet therapy and early 
invasive management have substantially reduced ischemia-related morbidity and mortality. This has been achieved 
at a higher risk of bleeding complications. Bivalirudin, a direct and specific thrombin inhibitor, represents an 
alternative to anticoagulation and platelet inhibition with heparin and glycoprotein IIb/IIIa inhibitor (GPI). The 
Acute Catherization and Urgent Intervention Triage Strategy (ACUITY) trial, a large, multicentre, prospective, 
randomised, open-label, parallel-group, Phase III trial, established the comparative clinical efficacy and safety of 
bivalirudin in patients with moderate- to high-risk NSTE-ACS [1]. In the overall ACUITY population, bivalirudin 
was associated with similar rates of ischemia and significantly reduced bleeding when compared with heparin plus 
GPI (H-GPI) [1,2]. In registration trials of planned PCI and acute myocardial infarction (MI), bivalirudin showed 
similar results and trended to improved mortality [3-5]. Such a trend was also evident in the ACUITY patients who 
received a thienopyridine prior to or post percutaneous coronary intervention (PCI) [2]. On this basis, the European 
Medicines Agency recently approved bivalirudin for patients with NSTE-ACS [6]. Co-administration of a 
thienopyridine is a conditional element of this approval. 
 
It remains unclear which groups of NSTE-ACS patients in the United Kingdom (UK) can benefit most from 
bivalirudin and health economic implications remain to be determined. Health economic evaluation studies based on 
data from multinational randomised clinical trials may not sufficiently take into account local epidemiological and 
clinical practice patterns. Local registry data can be used to overcome such limitations of external validity, albeit 
sometimes at the cost of compromising internal validity. The Global Registry of Acute Coronary Events (GRACE) 
is a large scale, multinational, observational study of ACS patients, with continuous recruitment from 1999 to 2007 
[7]. In the UK, four GRACE centres recruited 4,403 patients and included a subpopulation with qualifying 
characteristics similar to the ACUITY population. Bivalirudin was not used in these patients. 
 
Health economic evaluation studies compare costs and clinical effects of treatment strategies of interest against 
alternatives ideally representing current best practice. Where the treatment strategy of interest is more costly and 
also more clinically favourable than the comparator, an incremental cost-effectiveness ratio (ICER) is calculated as 
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the quotient of the cost difference between strategies and the difference in clinical effect between strategies (∆ cost / 
∆ effect). This work studies the incremental cost and cost-effectiveness of bivalirudin versus H-GPI in patients with 
NSTE-ACS from the perspective of the UK National Health Service (NHS). We reduced the problem of 
compromised external or internal validity by performing two parallel analyses, the first predominantly based on 
ACUITY and only making few key adjustments to reflect UK practice characteristics, the second using the UK 
GRACE registry population. 
 
 
METHODS 
 
Overview and patient population 
 
A model-based cost-utility analysis with a life-long time horizon evaluated the health economic endpoint of 
incremental cost per quality-adjusted life-year (QALY) gained. Cost-utility analysis follows the cost-effectiveness 
approach but expresses clinical effect as survival time adjusted for health-related quality of life. Quality of life 
weights (utilities) are gained from preference-based instruments, and are defined on a linear scale where 1 represents 
perfect health and 0 represents death. In this analysis, the population of interest was defined as acute NSTE-ACS 
patients at a medium to high risk of major cardiovascular events. Patients had to be planned for early or urgent 
invasive management, i.e. diagnostic angiography within 72 hours from admission followed by PCI, coronary artery 
bypass graft (CABG) surgery or conservative treatment, and had to receive a thienopyridine prior to or post 
angiography. 
 
In the ACUITY-based analysis, absolute and relative clinical event risks and most other model inputs were derived 
from the raw data of the H-GPI and bivalirudin alone arm patients who fulfilled the thienopyridine criterion (Figure 
1). Remaining life expectancy and long-term cardiovascular treatment costs of first-year survivors, unit costs and 
utilities were drawn from published UK sources. The strategies compared were those defined in the trial, i.e. H-GPI 
(with GPI started upstream prior to angiography, or initiated in the catheter laboratory if the patient was triaged to 
receive PCI) and bivalirudin alone (with the possibility of provisional, catheter laboratory-induced GPI use) [1]. 
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Fifty percent of H-GPI patients were randomised to upstream GPI. In consequence, 81% of H-GPI patients actually 
received GPI and 60% of these received it upstream. Eptifibatide use was substantial in ACUITY but in order to 
reflect approved indications and current UK practice, we assumed upstream GPI use to be tirofiban and catheter 
laboratory-initiated or provisional use to be abciximab. A GPI class effect was assumed and therefore, clinical event 
risks were not adjusted. 
 
In order to select a population with a similar risk profile for the GRACE-based analysis, GRACE patients were 
included if they had ACS but no acute ST segment elevation MI, diagnostic angiography within 72 hours from 
admission, and 6-month follow-up (Figure 1). In the interest of sample size, the exclusion criterion of no 
thienopyridine use was dropped. Absolute event risks and key medical resource use parameters (GPI use, length of 
stay) in the comparator strategy were drawn from GRACE. The other model inputs, inclusive of relative event risks 
in the bivalirudin strategy and assumptions on GPI substances used, were the same as in the ACUITY-based 
analysis. While an identical bivalirudin strategy was modelled, the comparator strategy in the GRACE-based 
analysis represented a routine practice mix of 29% H-GPI and 71% heparin alone use. As the proportion of upstream 
GPI use could not be extracted from the GRACE database, an assumption of 80% downstream use and 20% 
upstream use was made (unpublished Myocardial Ischaemia National Audit Project data). 
 
Baseline characteristics of the eligible ACUITY and GRACE patients, and initial treatment decisions, were 
remarkably similar although time from admission to catheterisation was longer in GRACE (Table 1). No relevant 
differences in baseline characteristics between the ACUITY study arms were noted (details not shown). 
[8]. 
Model structure 
 
A decision tree model was complemented with a Markov module to cover long-term survival (Figure 2). Virtual 
patient cohorts were followed from primary hospitalisation to death. Initial angiography was performed on all 
patients, who were then triaged to receive PCI, CABG or medical management. Between this initial treatment and 
end of the first year, patients could experience major and minor bleeding (until day 30), acute MI, repeat 
revascularisation, or die. Stroke events, which were rare in ACUITY and evenly distributed between study arms, 
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were not taken into account. After the first year, survival was modelled based on published life expectancies. The 
Markov module used two disease stages (alive/dead) and a cycle length of one year. A half-cycle correction was 
used for costs as well as effects. As simulated cohorts passed through the model, QALYs, medical resource use and 
costs accumulated. In the base case analyses, costs and effects were discounted at 3.5% as recommended by the UK 
National Institute for Health and Clinical Excellence [9]. 
 
Model inputs 
 
Clinical event risks 
 
ACUITY-based and GRACE-based comparator strategy event risks, and ACUITY-based relative event risks in the 
bivalirudin strategy, are shown in Table 2. GRACE-based risks were adjusted for differential follow-up times to 
enable ACUITY-based relative risks to be applied. CABG-related bleeding was disregarded in both analyses. The 
GRACE definition of major bleeding was slightly stricter than the ACUITY definition [10,11]. 
 
Long-term patient survival 
 
Based on Nottingham Heart Attack Register (NHAR) data, Palmer et al. estimated the average life expectancy of 6-
month ACS survivors to be 9.65 years [12]. We corrected this value for age differences between study populations 
based on UK life-tables and the DEALE method [13,14]. The resulting estimates of 10.39 years for the ACUITY-
based analysis and of 10.71 years for the GRACE-based analysis were converted to Markov transition probabilities. 
Patients entered our Markov module at 1 year but in light of potentially increased life expectancy due to medical 
progress since the NHAR data were collected, and as 1-year survivors may be healthier on average than 6-month 
survivors, no additional correction for this difference was applied. Long-term survival of 1-year survivors was 
assumed to be independent of the initial anticoagulation strategy. 
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Utilities 
 
We used EQ-5D-based health-state utility weights drawn from a study of 229 consecutive MI survivors discharged 
from a UK centre [15]. The authors assessed self-perceived health status at fixed time points post discharge, 
irrespective of clinical event occurrence, and provided average results. We assumed the six-week average of 0.68 to 
represent the situation in the first year after the event, and the one-year average of 0.72 to represent the situation in 
subsequent years. Valuation used the standard UK time trade-off value set, and results were comparable to UK 
estimates for patients undergoing PCI [16]. 
 
Medical resource use 
 
Anticoagulant use was modelled for the initial hospitalisation period, based on the frequencies of use observed in 
ACUITY and GRACE (Table 3). Duration of administration and amount of drug was only available from ACUITY. 
Unfractionated heparin (UFH) was disregarded due to its low cost. Non-integer numbers of GPI and bivalirudin 
vials were increased to the next integer to cover waste of left-overs. 
 
Days in normal ward and in intensive care unit (ICU)/coronary care unit (CCU) during the initial hospitalisation 
(Table 3) were assessed from ACUITY, irrespective of patient country of origin. This was justified by a very similar 
length of stay in the ACUITY H-GPI arm (mean±SD, 5.1±2.9 days) and in GRACE (mean±SD, 4.9±1.9 days). 
 
Other resource items or influential drivers of resource use in the first year included diagnostic angiographies, repeat 
revascularisation procedures (PCI or CABG) and clinical events. PCI was used in 82% and 88% of repeat 
revascularisations in ACUITY and GRACE, respectively. After the first year, long-term, cardiovascular-related 
medical resource use was represented by a literature-derived monetary amount. 
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Unit costs 
 
Unit costs for the year 2007/08 were drawn from UK sources or sources for England and Wales (Table 3). Where 
necessary, older unit costs were inflated to 2007/08 prices [17]. Drug prices were 2008 prices and remained 
unchanged in 2009 [18]. 
 
Unit costs for MI, PCI and CABG were based on Healthcare Resource Group (HRG)-based NHS reference costs 
[19,20]. Double-counting of ward costs during the initial hospitalisation period was avoided by estimating PCI and 
CABG procedure costs from the HRG costs on a pro-rata basis. We used a non-ward cost proportion of 55% for PCI 
[21] and a cost proportion of 30% incurred in theatre in cardiac surgery for CABG [22]. Non-Q-wave MIs occurring 
after initial hospitalisation discharge were assumed to cost 31% of a Q-wave MI [23]. The costs of MIs during the 
initial hospitalisation were covered by ward, angiography, PCI and CABG costs. 
 
The cost impact of ACS treatment-related and PCI-related bleeding is partially due to its influence on length of stay 
[24]. This element was covered by modelling initial hospitalisation ward costs; the ward costs of a small number of 
bleeds occurring after the initial hospitalisation period were disregarded. Additional examination and procedure 
costs of an ACUITY major bleed were estimated to be 75% of the procedure cost of a repeat PCI [25-27]. 
Transfusion costs were not added, in order to avoid double-counting. Minor bleeds were assumed to cost 6% of a 
major bleed [25]. 
 
Ward costs were based on NHS reference costs [19,28]. As cardiology ward costs might be influenced by procedure 
costs, the cost per day in general medicine was used as the unit cost for a normal ward day. The cost of an ICU day 
and a CCU day was averaged to represent the unit cost of an ICU/CCU day. 
 
Long-term annual cardiovascular treatment costs of NSTE-ACS survivors were estimated from a published model of 
thrombolysis versus primary PCI in MI patients, in the absence of NSTE-ACS-specific data [29]. Bravo Vergel et al. 
showed how the remaining life-time of 6-month MI survivors in the UK is distributed between a well state, a re-MI 
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state and a stroke state. They also provided an annual cost for each of these health states. Combining these elements 
allowed estimating an average annual cost. 
 
Sensitivity analysis 
 
Deterministic and probabilistic sensitivity analysis of the base case cost-effectiveness results was performed to 
assess the impact of parameter uncertainty around major model inputs. Comparator strategy event risks, relative 
events risks, and length of stay differences between strategies were varied based on 95% confidence intervals (CIs). 
Variation of HRG-based unit costs made use of accompanying interquartile ranges (IQRs). Utility scores and 
estimates of the remaining life-expectancy of 1-year ACS survivors were varied by ±25%. Estimates of bleed costs 
and of long-term annual cardiovascular treatment costs were varied by ±50% to reflect increased uncertainty. In 
probabilistic analysis, these ranges of variation were implemented using beta distributions for absolute event risks, 
lognormal distributions for relative event risks, normal distributions for length of stay differences, and triangular 
distributions for the remaining parameters. 
 
Additional scenario analyses addressed applicability of the base case results to UK medical practice. The proportion 
of upstream as opposed to catheter laboratory-induced GPI use was switched from 60% to 20% in the ACUITY-
based analysis and from 20% to 60% in the GRACE-based analysis, under the simplifying assumption of no changes 
in clinical effectiveness [30,31]. To capture change over time, the GRACE-based analysis was re-run with values for 
risk of death and overall GPI use as observed from 2002 onwards. To achieve a scenario more closely aligned with 
ACUITY, use of individual GPIs was set to the values observed in the trial, implying 60% eptifibatide use. A further 
scenario assumed initial hospitalisation to be of equal duration in both strategies. In order to reflect current practice 
in some UK centres, use of radial arterial access, which was 7% in ACUITY, was set to 30-80%. In this context, we 
conservatively assumed no access site bleeds in radial arterial access patients and correspondingly reduced length of 
stay differences between strategies. The occurrence, relative reduction and length of stay impact of organ bleeds 
were left unchanged. The discount rate was also varied, from 0-6%. 
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In the UK, the use of bivalirudin is by the interventional cardiologist only and the typical time period from start of 
administration to angiography is likely to be shorter than in ACUITY. Therefore, in an additional, exploratory 
analysis, bivalirudin use was restricted to 1 vial per patient. To maintain consistency between strategies, the number 
of tirofiban vials in the upstream GPI situation was also reduced to 1. Abciximab use, starting in the catheter 
laboratory only, was left unchanged. The simplifying assumption of no changes in clinical effectiveness was made. 
In the absence of robust data, this was justified by an additional subgroup analysis of N = 3,464 ACUITY patients 
with a time from randomisation to start of angiography of ≤ 4hours. Within this subgroup, N = 1,706 bivalirudin arm 
patients with non-missing drug use data had a median actual bivalirudin use of 0.6 vials, corresponding to 1 vial 
taking into account waste. Relative event risks (95% CIs) in the bivalirudin arm were similar to those reported in 
Table 2: 0.52 (0.38-0.73) for major bleeding, 0.60 (0.51-0.70) for minor bleeding, 1.22 (0.94-1.57) for myocardial 
infarction, 1.09 (0.90-1.32) for repeat revascularisation and 0.74 (0.51-1.08) for patient death. 
 
Technical implementation 
 
Derivations of model inputs and related statistical analyses were performed in Stata MP® (Stata Corporation, 
College Station, TX, USA). The model was implemented in TreeAge Pro 2008 Suite® (TreeAge, Inc., 
Williamstown, MA, USA). Probabilistic sensitivity analyses used 10,000 sets of randomly drawn input parameters.  
 
 
RESULTS 
 
Survival 
 
In the ACUITY-based analysis, undiscounted survival was predicted to be 10.82 years in the H-GPI strategy and 
10.87 years in the bivalirudin strategy. Corresponding results in the GRACE-based analysis were 10.89 and 10.95 
years, respectively.  
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Cost and cost effectiveness 
 
Cost differences between strategies and ICERs are shown in Table 4. The bivalirudin strategy was characterised by 
higher anticoagulant costs but lower initial hospitalisation and bleed costs than in the H-GPI strategy. The 
incremental cost for the bivalirudin strategy was £250 and £423 in the ACUITY-based and GRACE-based analyses, 
respectively, and incremental gains were 0.025 and 0.034 QALYs, which resulted in ICERs of £9,906 and £12,276 
per QALY gained. 
 
Sensitivity analysis 
 
Deterministic sensitivity analysis exploring the impact of parameter uncertainty identified no overly influential 
parameters. ICERs (detailed in the Appendix) remained distinctly below the threshold of £20,000 per QALY gained, 
except when relative risk of death was set to its upper 95% CI limit. Given a non-significant p value of 0.283, the 
bivalirudin strategy was necessarily dominated in this situation with a per-patient loss of 0.024 and 0.032 QALYs in 
the ACUITY-based and GRACE-based analyses, respectively, and an additional cost of £196 and £348. In 
probabilistic sensitivity analysis, 7,214 (72.1%) and 6,701 (67.0%) of 10,000 simulation results were more cost-
effective than £20,000 per QALY gained, in the ACUITY-based (Figure 3 and Appendix) and GRACE-based 
analyses. 
 
The additional sensitivity analyses exploring clinical and health economic scenarios yielded ICERs close to or better 
than £15,000 per QALY gained. The assumption of radial arterial access use in 80% of patients led to ICERs of 
£12,809 and £14,403, respectively, in the ACUITY-based and GRACE-based analyses. In the ACUITY-based 
analysis, adjusting the proportion of catheter laboratory-initiated GPI use towards higher proportional use as seen in 
UK practice, led to a favourable ICER of £1,872 per QALY gained. Restricting bivalirudin and tirofiban use to 1 
vial per patient also led to favourable results. In the ACUITY-based analysis, bivalirudin became dominant under 
this assumption with a per-patient gain of 0.025 QALYs and saving of £75. In the GRACE-based analysis, the ICER 
improved to £2,287 per QALY gained. Details are shown in the Appendix. 
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DISCUSSION 
 
We assessed the cost-effectiveness of bivalirudin versus H-GPI in NSTE-ACS patients with at a medium to high risk 
of major cardiovascular events and undergoing an early or urgent invasive management strategy, from the 
perspective of the UK NHS. Two parallel analyses were performed. The first was predominantly based on the 
ACUITY trial, implying high internal consistency and guideline-driven treatment strategies [1] but potentially 
limited applicability to local medical practice. The second made use of UK data from the GRACE registry, to the 
extent possible, and reflected local practice more closely but implied reduced internal consistency of model inputs. 
Both analyses yielded ICERs for bivalirudin well below £20,000 per QALY gained. A bivalirudin strategy coupled 
with thienopyridine use remained cost-effective even when subjected to extensive sensitivity analyses. 
 
This result is compatible with earlier economic findings. In a bottom-up cost study of US ACUITY patients, 
bivalirudin was less costly than H-GPI at 30 days [27]. Such an absolute cost advantage was not visible in our 
analysis, presumably due to differences in US and UK practice patterns, resource use and cost structure. Lack of 
detailed economic data for patients enrolled outside the US precluded an in-depth comparison. However, 
anticoagulant costs were higher in the bivalirudin strategy and other initial hospitalisation costs were lower, in both 
cases. Studies of PCI patients, based on the Randomized Evaluation in PCI Linking Angiomax to Reduced Clinical 
Events-2 (REPLACE-2) trial, also showed bivalirudin to be cost-saving or dominant [25,32]. 
 
Some comments are needed to reflect the applicability of our findings to UK practice. We assumed upstream GPI 
use to be tirofiban and catheter laboratory-initiated or provisional use to be abciximab. This reflects the approach 
taken in most UK clinical centres. Under the assumption of 60% eptifibatide use, cost-effectiveness was also 
maintained. In the ACUITY-based analysis, upstream GPI use, implying relatively low-cost tirofiban or eptifibatide, 
was proportionally higher than in UK practice, which disfavoured bivalirudin. In UK practice, bivalirudin is 
predominately initiated in the catheter laboratory and typical use is expected to be 1 vial per patient. In the absence 
of robust data on clinical implications, we performed an exploratory subgroup analysis of ACUITY patients with a 
time from randomisation to start of angiography of ≤ 4 hours. Similar relative risk results as in the main analysis 
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justified an approximate evaluation of the 1-vial situation, which yielded superior cost-effectiveness results for 
bivalirudin. Finally, testing the impact of increased use of radial arterial access and conservatively assuming no 
access site bleedings in these patients, irrespective of anticoagulation strategy used, did not affect health economic 
conclusions. In combination, these findings imply that the cost-effectiveness of bivalirudin in routine UK practice 
may be further improved over our base case ICER results and that, in some patient groups, bivalirudin may be 
dominant. 
 
There are some limitations. QALY gains were based on a non-significant relative risk of death at 1 year. The 
ACUITY trial was not powered to demonstrate a survival advantage but all recent bivalirudin trials trended to 
improved mortality, more distinctly so in patients who also received a thienopyridine [2-4]. Probabilistic sensitivity 
analysis is the appropriate methodology to correctly incorporate and assess the impact of such parameter uncertainty 
arising from clinical trial results [33]. In the GRACE-based analysis, a substantial proportion of patients in the 
comparator strategy received heparin only but bivalirudin was assumed to be used in all patients in this projection. 
Relative risks were not adjusted for increased cardiovascular risk or decreased bleeding risk in those GRACE 
patients who received heparin only, due to lack of suitable data. For similar reasons, relative risks and costs were not 
corrected for lack of thienopyridine treatment in 12% of the included GRACE patients. In the absence of suitable 
input data, the modelling did not link long-term survival and cost to risk changes in other clinical events or to the 
occurrence of MIs or bleeds during the first year. Due to a lack of quality bleeding cost data, we relied on a 
comparison of the impact of bleeds and PCI procedures on hospitalisation costs, as assessed by multivariate 
regression analyses [25,26]. No disutility was applied to patients with bleeding complications. Given a lack of 
longer-term data, we assumed equal average life expectancy of 1-year survivors in both strategies. Some advantages 
of bivalirudin with a potential for economic impact, such as reduced anticoagulation monitoring requirements, were 
not taken into account in the modelling. 
 
Bivalirudin has been shown to efficiently reduce the occurrence of access site and organ bleeds in NSTE-ACS 
patients and related patient populations [1,3,4]. This has economic as well as clinical implications. An association of 
major bleeds with mortality has been reported [34]. In planned PCI and in the ACUITY patients who received a 
thienopyridine prior to or post PCI, bivalirudin trended to improved mortality [2,3]. Consistent with these findings, a 
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statistically significant survival effect at 30 days and at one year was observed in the HORIZONS-AMI trial of acute 
MI patients undergoing primary PCI [4,5]. A large, retrospective US database study of nearly 130'000 patients 
undergoing inpatient PCI confirmed the repeatability of the effects on bleeds and survival in routine practice [35]. 
 
From a UK NHS perspective, bivalirudin is likely to be cost-effective in NSTE-ACS patients who are at a moderate 
to high risk of major cardiovascular events, undergo early or urgent invasive management otherwise involving GPI 
use, and receive a thienopyridine. 
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Table 1. Baseline and initial treatment characteristics 
Characteristic ACUITY patientsa GRACE UK NSTE-
ACS patients with 
diagnostic angiography 
within 72 hoursb 
All GRACE UK NSTE-
ACS patients 
 N  N  N  
Age; mean years±SD 7,523 62.6±11.5 557 61.3±10.9 3,542 64.7±12.0 
Weight; mean kg±SD 7,518 85.5±18.3c 504 78.6±15.3 2,766 78.1±16.7 
Female; patients (%) 7,523 2,179 (29.0) 557 161 (28.9) 3,544 1,217 (34.3) 
Diabetes; patients (%) 7,472 2,098 (28.1)d 556 87 (15.6) 3,538 527 (14.9) 
Elevated cardiac biomarkers; 
patients (%)e 
6,970 4,255 (61.1) 527 269 (51.0) 3,406 1,387 (40.7) 
ST-segment deviation ≥1mm; 
patients (%) 
7,520 2,610 (34.7) 557 188 (33.8) 3,549 1,160 (32.7) 
GRACE risk score [8]; 
mean±SD 
1,265 112±29f 487 117±30 3,185 122±34 
Time from admission to 
angiography; median hours 
7,486 19.7 557 27.5 958 59.1 
PCI, patients (%) 7,523 5,026 (66.8) 557 362 (65.0) 3,549 893 (25.2) 
CABG, patients (%) 7,523 591 (7.9) 557 50 (9.0) 3,549 54 (4.6) 
Thienopyridine use, patients (%) 7,523 7,523 (100.0) 557 490 (88.0) 3,549 1,972 (55.6) 
a Basis for ACUITY-based cost-effectiveness analysis. 
b Basis for GRACE-based cost-effectiveness analysis. 
c For 103 ACUITY patients enrolled in UK, mean±SD, 79.9±13.1 kg. 
  
d For 95 ACUITY patients enrolled in UK, frequency (%), 15 (15.8). 
e GRACE criterion: > 2x upper limit of normal of CK-MB or, if not available, of CK or > upper limit of normal 
of troponin. ACUITY criterion: any increase. 
f Assuming Killip class 1. Score calculation impossible for many patients due to missing heart rate and blood 
pressure data. 
CABG, coronary artery bypass graft; CK, creatinin kinase; CK-MB, creatinin kinase isoenzyme MB; NSTE-ACS, 
non-ST-segment elevation acute coronary syndrome; PCI, percutaneous coronary intervention; SD, standard 
deviation; UK, United Kingdom. 
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Table 2. Absolute and relative event risks 
Parameter ACUITY patients, H-
GPI arm 
GRACE UK NSTE-ACS 
patients with diagnostic 
angiography within 72 
hours 
ACUITY patients, 
bivalirudin arm 
compared to H-GPI 
arm 
 N Patients (%; 
95% CI) 
N Patients (%; 
95% CI)a 
N Relative event 
risk (95% CI) 
Non-CABG-related major 
bleedb 
3,730 216 (5.8; 5.1-
6.6) 
549 24 (4.4; 2.8-
6.4) 
7,523 0.57; 0.46-
0.71 
Non-CABG-related minor 
bleed 
3,730 873 (23.4; 
22.1-24.8) 
n/a 96 (17.7; 11.2-
25.6)c 
7,523 0.59; 0.54-
0.66 
MId 3,730 258 (6.9; 6.1-
7.8) 
345 16 (4.6; 2.7-
7.4) 
7,523 1.124; 0.96-
1.32 
Repeat or unplanned 
revascularisation 
3,730 342 (9.2; 8.3-
10.1) 
557 73 (13.1; 10.4-
16.2) 
7,523 1.00; 0.87-
1.15 
Death 3,730 136 (3.6; 3.1-
4.3) 
557 27 (4.8; 3.2-
7.8)e 
7,523 0.88; 0.69-
1.11 
a Based on comparison of event risks in ACUITY at different time points, bleeding risks in GRACE were 
adjusted to represent 30 day risk and other event risks in GRACE were adjusted to represent 1 year risk. 
b The GRACE definition of major bleeding was slightly stricter than the ACUITY definition [10,11]. 
c Not recorded in GRACE, therefore estimated on a pro-rata basis. 
d Information on MI occurrence available in GRACE from 2002 on. The proportion of Q-wave MIs in ACUITY 
was 113 of 553 (20.4%). 
e In GRACE patients enrolled from 2002 on, the estimated risk of death in year 1 was 14 of 357 (3.9%). 
2 of 2 
CABG, coronary artery bypass graft; CI, confidence interval; GPI, glycoprotein IIb/IIIa inhibitor; H, heparin; MI, 
myocardial infarction; n/a, not available; NSTE-ACS, non-ST-segment elevation acute coronary syndrome; UK, 
United Kingdom. 
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Table 3. Medical resource use parameters and unit costs (£) 
Parameter ACUITY-based 
analysis 
GRACE-based 
analysis 
Anticoagulant use, % patients 
 LMWH (H-GPI) 
 
54.3a 
 
70.2a 
 GPI (H-GPI) 81.2 29.9 
 Bivalirudin (bivalirudin) 99.3 
assume same 
 GPI (provisional; bivalirudin) 8.7 
Anticoagulant vial numbers, mean (95% CI)b 
 Enoxaparin 300 mg (H-GPI)c 
 
0.76 (0.73-0.79) 
 
0.74 (0.70-0.77)d 
 Tirofiban 12.5 mg (upstream; H-GPI) 1.49 (1.44-1.54) 1.47 (1.42-1.52)d 
 Abciximab 10 mg (catheter laboratory; H-GPI) 3.25 (3.20-3.29) 3.17 (3.14-3.20)d 
 Bivalirudin 250 mg (bivalirudin) 2.17 (2.12-2.22) 2.13 (2.08-2.19)d 
 Abciximab 10 mg (provisional; bivalirudin) 3.37 (3.27-3.48) 3.12 (3.06-3.17)d 
Initial hospitalisation, mean days (95% CI) 
 Normal ward (H-GPI) 
 
3.39 (3.32-3.47) 
assume same  Normal ward (bivalirudin) 3.27 (3.20-3.34) 
 ICU/CCU (H-GPI) 1.51 (1.46-1.56) 
 ICU/CCU (bivalirudin) 1.44 (1.39-1.49) 
Drug costs [18] 
 Enoxaparin (Clexane®) 300 mg multidose vial 
 
22 
 Abciximab (ReoPro®) 10 mg vial 260 
2 of 3 
 Eptifibatide (Integrilin®) 20 mg/75 mg vial 14.45/45.42 
 Tirofiban (Aggrastat®) 12.5 mg vial 146 
 Bivalirudin (Angiomax®) 250 mg vial 310 
Event and procedure costs 
 Angiography procedure cost (IQR) [20] 
 
268 (254-474) 
 PCI cost (IQR) [19] 2,614 (2,087-2,955) 
 PCI procedure cost (IQR)e [19, 21] 1,438 (1,148-1,625) 
 CABG cost (IQR) [19] 8,631 (7,456-10,212) 
 CABG procedure cost (IQR)e [19, 22] 2,624 (2,267-3,104) 
 Q-wave MI (IQR) [19] 1,934 (882-2,376) 
 Non-Q-wave MI (IQR) [19, 23] 600 (274-737) 
 Major bleed examination and procedure coste [19,25,26] 1,078 
 Minor bleed examination and procedure coste [19,25,26] 67 
Ward costs 
 Normal ward day (IQR) [28] 
 
257 (251-275) 
 CCU/ICU day (IQR) [19] 938 (777-1,060) 
Long-term annual cardiovascular treatment cost of 1-year survivors 
[29] 
851 
a Including 8.5% ACUITY patients and 47.2% GRACE patients with other anticoagulants in addition to LMWH. 
b Per applicable patient. 
c LMWH was assumed to be enoxaparin, as in the majority of patients. Dose was converted to fractions of 
Clexane® 300 mg multidose vials, for technical simplicity. 
d ACUITY-based vial numbers adjusted to GRACE weight distribution. 
e Excluding ward costs. 
3 of 3 
ACS, acute coronary syndrome; CABG, coronary artery bypass graft; CCU, coronary care unit; CI, confidence 
interval; GPI, glycoprotein IIb/IIIa inhibitor; H, heparin; ICU, intensive care unit; IQR, interquartile range; LMWH, 
low molecular weight heparin; MI, myocardial infarction; PCI, percutaneous coronary intervention. 
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Table 4. Base case cost (£ per patient; amounts represent averages across all patients without and with 
events) and cost-effectiveness results 
Parameter ACUITY-based analysis GRACE-based analysis 
 Bivalirudin H-GPI Difference Bivalirudin H-GPI Difference 
Cost of LMWH and GPIa 76 390 -314 71 218 -147 
Cost of bivalirudin 668 0 668 656 0 656 
Cost of angiographies, PCI and 
CABGb 
1,624 1,625 1 1,781 1,781 0 
Cost of MIs post initial 
hospitalisation 
31 28 3 14 13 1 
Cost of bleedsc 45 78 -33 34 59 -25 
Ward cost (initial hospitalisation) 2,189 2,291 -102 2,123 2,224 -101 
Total 1-year cost 4,633 4,412 221 4,679 4,295 384 
Long-term cardiovascular 
treatment cost after year 1d 
6,270 6,241 29 6,342 6,303 39 
Total costd 10,903 10,653 250 11,021 10,598 423 
QALYs per patientd 5.959 5.934 0.025 6.016 5.982 0.034 
ICER (£ per QALY gained)d 9,906 12,276 
a Cost of unfractionated heparin treated as zero. 
b Procedure costs during the initial hospitalisation and full costs thereafter. 
c Examination and procedure costs of bleeds until day 30. 
d Discounted at 3.5% per year. 
2 of 2 
CABG, coronary artery bypass graft; GPI, glycoprotein IIb/IIIa inhibitor; H, heparin; ICER, incremental cost-
effectiveness ratio; LMWH, low molecular weight heparin; MI, myocardial infarction; PCI, percutaneous coronary 
intervention; QALY, quality-adjusted life year. 
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Figure legends 
 
Figure 1. Patient basis for derivation of model inputs. GPI, glycoprotein IIb/IIIa inhibitor; STEMI, ST-segment 
elevation myocardial infarction; NSTE-ACS, non-ST-segment elevation acute coronary syndrome; PCI, 
percutaneous coronary intervention; UK, United Kingdom. 
 
Figure 2. Structure of decision analytic model. Model nodes (circles) denoted as clones indicate the use of identical 
substructures. For example, the structure to the right of the leftmost thick line (denoted as 'Bivalirudin') defines 
clone 1. Clone 1 is re-used for the 'Heparin + GPI' strategy. Anticoagulation strategy-specific behaviour of the 
model is achieved by using an indicator variable for anticoagulation strategy, and formulae dependent hereupon. 
This allows, e.g., to trigger the use of relative event risks as required. Differential clinical effects as a function of 
primary treatment strategy (PCI, CABG or conservative treatment) could be implemented in the same way. 
However, this possibility was not used in order to avoid extensive subgrouping and to contain statistical uncertainty. 
 
Figure 3. ACUITY-based analysis – probabilistic sensitivity analysis result. QALYs, quality-adjusted life-years. 
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Appendix – Additional sensitivity analysis results 
 
Table A1. Deterministic sensitivity analysis of ACUITY-based cost-effectiveness results, exploring the 
impact of statistical uncertainty 
Varied parameter Favours heparin-based 
strategy 
Favours bivalirudin-based 
strategy 
 Varied 
parameter 
values 
ICER  
(£ per QALY 
gained) 
Varied 
parameter 
values 
ICER  
(£ per QALY 
gained) 
Base case -- 9,906 -- 9,906 
Risk of major / minor bleed in 
heparin-based strategy 
5.1% / 
22.1% 
10,049 6.6% / 
24.8% 
9,744 
Risk of MI / repeat revascularization 
in heparin-based strategy 
7.8% /  
10.1% 
9,924 6.1% /  
8.3% 
9,890 
Risk of death in heparin-based 
strategy 
3.1% 11,324 4.3% 8,475 
Relative risk of major / minor bleed 
under bivalirudin-based strategy 
0.706 /  
0.655 
10,283 0.459 /  
0.538 
9,599 
Relative risk of MI / repeat 
revascularisation under bivalirudin-
based strategy 
1.321 /  
1.154 
12,048 0.957 /  
0.868 
8,072 
Relative risk of death under 
bivalirudin-based strategy 
1.113 Bivalirudin 
strategy 
dominated, 
∆cost, £196, 
∆QALY -
0.024 
0.694 4,592 
Life expectancy of year-1 survivors 7.79 11,832 12.99 8,748 
Utility of ACS patients,  
first year / subsequent years 
0.396 / 0.353 11,005 0.238 / 0.212 9,017 
2 
Difference in index hospitalisation 
length of stay (days) between 
strategies, normal ward / CCU+ICU 
-0.01 / -0.00 13,721 -0.23 / -0.14 6,378 
PCI cost / PCI procedure cost (£) 2,955 / 1,625 9,906 2,087 / 1,148 9,906 
CABG cost / CABG procedure cost 
(£) 
10,012 /  
3,104 
9,906 7,456 /  
2,267 
9,906 
Q-wave / non-Q-wave MI cost (£) 2,376 / 737 9,937 882 / 274 9,832 
Major / minor bleed cost (£) 539 / 34 10,564 1,617 / 101 9,245 
Long-term treatment cost of NSTE 
ACS patients (£ per year) 
1,277 10,464 426 9,348 
 
ACS, acute coronary syndrome; CABG, coronary artery bypass graft; CCU, coronary care unit; ICER, 
incremental cost-effectiveness ratio; ICU, intensive care unit; MI, myocardial infarction; NSTE ACS, non-ST-
segment elevation acute coronary syndrome; PCI, percutaneous coronary intervention; QALY, quality-adjusted 
life year. 
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Table A2. Deterministic sensitivity analysis of GRACE-based cost-effectiveness results, exploring the 
impact of statistical uncertainty 
Varied parameter Favours heparin-based 
strategy 
Favours bivalirudin-based 
strategy 
 Varied 
parameter 
values 
ICER  
(£ per QALY 
gained) 
Varied 
parameter 
values 
ICER  
(£ per QALY 
gained) 
Base case - 12,276 - 12,276 
Risk of major / minor bleed in 
heparin-based strategy 
2.8% / 
11.2% 
12,544 6.4% / 
25.6% 
11,944 
Risk of MI / repeat revascularization 
in heparin-based strategy 
7.4% / 
16.2% 
12,304 2.7% / 
10.4% 
12,258 
Risk of death in heparin-based 
strategy 
3.2% 17,856 7.8% 7,984 
Relative risk of major / minor bleed 
under bivalirudin-based strategy 
0.706 /  
0.655 
12,486 0.459 /  
0.538 
12,105 
Relative risk of MI / repeat 
revascularisation under bivalirudin-
based strategy 
1.321 /  
1.154 
14,187 0.957 /  
0.868 
10,639 
Relative risk of death under 
bivalirudin-based strategy 
1.113 Bivalirudin 
strategy 
dominated, 
∆cost, £348, 
∆QALY -
0.032 
0.694 5,530 
Life expectancy of year-1 survivors 8.03 14,712 13.39 10,812 
Utility of ACS patients,  
first year / subsequent years 
0.396 / 0.353 13,638 0.238 / 0.212 11,175 
4 
Difference in index hospitalisation 
length of stay (days) between 
strategies, normal ward / CCU+ICU 
-0.01 / -0.00 15,078 -0.23 / -0.14 9,762 
PCI cost / PCI procedure cost (£) 2,955 / 1,625 12,276 2,087 / 1,148 12,276 
CABG cost / CABG procedure cost 
(£) 
10,012 /  
3,104 
12,276 7,456 /  
2,267 
12,276 
Q-wave / non-Q-wave MI cost (£) 2,376 / 737 12,287 882 / 274 12,252 
Major / minor bleed cost (£) 539 / 34 12,643 1,617 / 101 11,910 
Long-term treatment cost of NSTE 
ACS patients (£ per year) 
1,277 12,835 426 11,718 
 
ACS, acute coronary syndrome; CABG, coronary artery bypass graft; CCU, coronary care unit; ICER, 
incremental cost-effectiveness ratio; ICU, intensive care unit; MI, myocardial infarction; NSTE ACS, non-ST-
segment elevation acute coronary syndrome; PCI, percutaneous coronary intervention; QALY, quality-adjusted 
life year. 
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Table A3. Additional deterministic sensitivity analysis of ACUITY-based cost-effectiveness results, 
exploring clinical and health economic scenarios 
Varied parameters Favours heparin-based 
strategy 
Favours bivalirudin-based 
strategy 
 Varied 
parameter 
values 
ICER  
(£ per QALY 
gained) 
Varied 
parameter 
values 
ICER  
(£ per QALY 
gained) 
Base case -- 9,906 -- 9,906 
Anticoagulant use 
Upstream GPI use (expressed as a 
proportion of all GPI use) in heparin 
plus GPI strategy 
-- -- 20% 1,872 
Proportional GPI use 
(abciximab/eptifibatide/tirofiban) 
As seen in 
ACUITYa 
14,581 -- -- 
Per-patient number of bivalirudin 250 
mg vials in bivalirudin strategy and 
of tirofiban 12.5 mg vials in heparin 
plus GPI strategy (upstream GPI 
use)b 
--  Biv., 1 vial;  
Tiro. 1 vial 
Dominant, 
saves £75 and 
gains 0.025 
QALYs per 
patient 
Bleeds 
Radial arterial access site use 
(assuming no access-site bleeds in 
radial access patients)c 
30% 
80% 
10,983 
12,809 
-- -- 
Index hospitalisation length of stay 
Index hospitalisation length of stay Equal in 
both 
strategies 
13,914   
Discounting 
Discount rate 6% 11,340 0% 7,846 
6 
a Proportional GPI use in the heparin plus upstream GPI arm, expressed as a percentage of all patients 
included in this analysis and receiving GPI, was abciximab 1%, eptifibatide 63%, tirofiban 36%. 
Percentages in the heparin plus catheter laboratory GPI arm were abciximab 37%, eptifibatide 58%, 
tirofiban 5%. Provisional GPI use in the bivalirudin alone arm was abciximab 35%, eptifibatide 53%, 
tirofiban, 11%. 
b Assumes no difference in clinical outcomes. 
c Difference in length of stay between strategies adjusted proportional to reduction in avoidance of major 
bleeds, conservatively assuming the entire length of stay reduction in the bivalirudin strategy to be due 
to effect on bleeds. 
GPI, glycoprotein IIb/IIIa inhibitor; ICER, incremental cost-effectiveness ratio; QALY, quality-adjusted life 
year. 
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Table A4. Additional deterministic sensitivity analysis of GRACE-based cost-effectiveness results, 
exploring clinical and health economic scenarios 
Varied parameters Favours heparin-based 
strategy 
Favours bivalirudin-based 
strategy 
 Varied 
parameter 
values 
ICER  
(£ per QALY 
gained) 
Varied 
parameter 
values 
ICER  
(£ per QALY 
gained) 
Base case -- 12,276 -- 12,276 
Anticoagulant use 
Upstream GPI use (expressed as a 
proportion of all GPI use) in heparin 
plus GPI strategy 
60% 14,386 -- -- 
Proportional GPI use 
(abciximab/eptifibatide/tirofiban) 
As seen in 
ACUITYa 
15,115 -- -- 
Per-patient number of bivalirudin 250 
mg vials in bivalirudin strategy and 
of tirofiban 12.5 mg vials in heparin 
plus GPI strategy (upstream GPI 
use)b 
-- -- Biv., 1 vial;  
Tiro. 1 vial 
2,287 
Anticoagulant use and risk of death 
Risk of death and all GPI use in 
GRACE patients as seen from 2002 
on 
Risk of 
death, 3.9%; 
GPI use 
38.5% 
12,686 -- -- 
Bleeds 
Radial arterial access site use 
(assuming no access-site bleeds in 
radial access patients)2 
30% 
80% 
12,838 
14,403 
-- -- 
Index hospitalisation length of stay 
8 
Index hospitalisation length of stay Equal in 
both 
strategies 
15,219 -- -- 
Discounting 
Discount rate 6% 14,144 0% 9,593 
a Assumes no difference in clinical outcomes. 
b Difference in length of stay between strategies adjusted proportional to reduction in avoidance of major 
bleeds, conservatively assuming the entire length of stay reduction in the bivalirudin strategy to be due 
to effect on bleeds. 
GPI, glycoprotein IIb/IIIa inhibitor; ICER, incremental cost-effectiveness ratio; QALY, quality-adjusted life 
year. 
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Appendix figure legends 
 
Figure A1. ACUITY-based analysis – Tornado diagram of impact of parameter uncertainty on cost-effectiveness 
result. ACS, acute coronary syndrome; CABG, coronary artery bypass graft; GPI, glycoprotein IIb/IIIa inhibitor; 
ICU, intensive care unit; MI, myocardial infarction; NSTE-ACS, non-ST-segment elevation acute coronary 
syndrome; QALY, quality-adjusted life-year; RR, relative risk; STEMI, ST-segment elevation myocardial 
infarction; PCI, percutaneous coronary intervention. 
 
Figure A2. ACUITY-based analysis – cost-effectiveness acceptability curve. QALY, quality-adjusted life-year. 
 


